Intermittent treatment of BRAF V600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge

Defining and Targeting BRAF Mutations in Solid Tumors

(2021) Briana R. Halle et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?

(2021) Federica Giugliano et al.   CANCER TREATMENT REVIEWS

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

(2021) Anna Stagno et al.   Frontiers in Oncology

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

(2021) Maria Gonzalez-Cao et al.   Nature Communications

Towards Multidrug Adaptive Therapy

(2020) Jeffrey West et al.   CANCER RESEARCH

Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies

(2020) Derek S. Park et al.   CANCER RESEARCH

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

(2020) Alain P. Algazi et al.   NATURE MEDICINE

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS ‐Mutant Melanoma

(2020) Alexandra Valeska Matter et al.   ONCOLOGIST

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

(2020) Ilaria Proietti et al.   Cancers

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

(2020) Lokeswari P. Tangella et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Mitogen-activated protein kinase blockade in melanoma

(2020) Pauline Tétu et al.   CURRENT OPINION IN ONCOLOGY

Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma

(2019) Xiaoxia Zhu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma

(2019) Ileine M Sanchez et al.   MOLECULAR CANCER THERAPEUTICS

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities

(2019) Florian Rambow et al.   GENES & DEVELOPMENT

The great escape: tumour cell plasticity in resistance to targeted therapy

(2019) Soufiane Boumahdi et al.   NATURE REVIEWS DRUG DISCOVERY

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma

(2019) Inna Smalley et al.   EBioMedicine

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

(2019) Coralie Reger de Moura et al.   Translational Oncology

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

(2018) Sara Valpione et al.   EUROPEAN JOURNAL OF CANCER

Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy

(2018) Ann-Kathrin Ernst et al.   PLoS One

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study

(2018) Julia K. Tietze et al.   Oncotarget

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

(2017) Helen L. Young et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

(2017) Max Schreuer et al.   LANCET ONCOLOGY

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

(2017) Mohammad Fallahi‐Sichani et al.   Molecular Systems Biology

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

(2017) Xiangjun Kong et al.   NATURE

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

(2017) Yaohua Xue et al.   NATURE MEDICINE

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

(2017) Yapeng Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer

(2017) Jingsong Zhang et al.   Nature Communications

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

(2017) Aayoung Hong et al.   Cancer Discovery

New role of ID3 in melanoma adaptive drug-resistance

(2017) Sachindra   et al.   Oncotarget

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment

(2014) Yuen-Keng Ng et al.   MELANOMA RESEARCH

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

(2014) Andrew J. Dooley et al.   Therapeutic Advances in Medical Oncology

A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

(2013) Julie Caramel et al.   CANCER CELL

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

(2013) J. F. Grippo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer

(2012) A. S. Silva et al.   CANCER RESEARCH

EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation

(2012) Helena Kiefel et al.   CARCINOGENESIS

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells

(2011) Ling Yu et al.   IMMUNOLOGIC RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition

(2011) Thomas Metzner et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

(2011) Ossia M. Eichhoff et al.   Pigment Cell & Melanoma Research

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

(2010) R. B. Corcoran et al.   Science Signaling